Clinical Trial

DapagliFLOzin in Renal AL Amyloidosis (FLORAL)

Study acronym: FLORAL
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn if an oral drug called dapagliflozin is safe and can reduce high protein levels in the urine of patients with renal amyloid light-chain (AL) amyloidosis using a decentralized study design. Participants will be: * screened for the trial via an online platform * contacted by study personal to obtain electronic consent * enrolled in the trial if eligible and consented * contacted by study personal for further instructions and directions * sent dapagliflozin oral medication (supplied by the site pharmacy) * followed up regularly with the study team via telemedicine or other online avenues * monitored using lab work, inquiries about side effects and assessment of protocol adherence at 1 month, 3 months and 6 months * continue treatment for 6 months
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-05-14; most recent amendment 2026-06-23.
Status change: Not Yet Recruiting → Recruiting 2025-01-07
Trial Details
NCT Number NCT06420167
Lead Sponsor Barbara Ann Karmanos Cancer Institute
Conditions Renal AL Amyloidosis
Enrollment 20 participants
Start Date 2024-07-11
Primary Completion 2027-04 (estimated)
Study Completion 2028-04 (estimated)
Updated on ClinicalTrials.gov 2026-06-26